Maltodextrin
Insulin Sensitivity/Resistance
Virginia Polytechnic Institute and State UniversityN/AActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 89/ 100
Competitive context
6 Active assets in the Insulin Sensitivity/Resistance cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Semaglutide Nordsjaellands Hospital | Phase 3 | B |
Vericiguat University of Alabama at Birmingham | Phase 2 | CCC |
Letrozole Cairo University | Early Phase 1 | C |
Metformin Cairo University | Early Phase 1 | C |
Humulin R University of Copenhagen | N/A | D |
Sucralose Virginia Polytechnic Institute and State University | N/A | D |
Same molecule, other indications
Maltodextrin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →